Summary
A bioRxiv preprint associates a platelet-related circulating tumour-cell profile in breast cancer with poorer overall survival. It also proposes a CD40LG–ITGA5:ITGB1 signal involving monocytes as a candidate for further study.
A bioRxiv preprint reports that a subset of circulating tumour cells (CTCs) in breast cancer has platelet-related features and that a greater estimated proportion of these cells is associated with poorer overall survival. The researchers also propose a possible signal between CTCs and monocytes, an immune-cell type, through the CD40LG–ITGA5:ITGB1 molecular pair. The findings come from analyses of gene-expression data and computational modelling.
CTCs are cancer cells found in the bloodstream. Platelets can help protect them from immune surveillance, but the authors say CTCs with platelet markers and their communication with monocytes have not been thoroughly investigated. The study uses the term “Platelet-Programmed CTCs” for tumour cells with platelet-related characteristics; it does not refer to platelets themselves.
A platelet-related cell profile and survival association
The researchers analysed single-cell RNA-sequencing data from 377 CTCs and 2,634 white blood cells. Their trajectory analysis identified a CTC subpopulation with enhanced platelet-related functions, including platelet aggregation and a profile associated with resistance to natural killer (NK) cell-mediated killing. Trajectory analysis infers patterns of related cell states from data; the reported result is not, by itself, a direct test of how these cells behave in the body.
To estimate how common this cell profile was in primary breast tumours, the team applied the Dampened Weighted Least Squares method to bulk RNA-sequencing data from 1,102 samples. Bulk sequencing measures gene activity across a mixture of cells, so the method was used to estimate the proportion attributed to platelet-programmed tumour cells.
A higher estimated proportion was associated with poorer overall survival. The authors report a hazard ratio of 6 per 10% increase in that proportion (95% confidence interval 1.76–20.7; Cox proportional-hazards p=0.00419). They found no statistically significant difference in the association between early- and late-stage patients. This is an observational association: the survival analysis identifies a relationship in the dataset rather than testing whether the cell profile causes poorer outcomes.
A proposed signal from tumour cells to monocytes
Cell–cell communication analysis and molecular docking led the researchers to nominate CD40LG–ITGA5:ITGB1 as a possible immune-checkpoint axis involving monocytes. ITGA5 and ITGB1 encode subunits of the alpha-5/beta-1 integrin. The proposed connection could offer a way to investigate how platelet-programmed CTCs interact with immune cells, but the analysis identifies a candidate rather than an established signalling mechanism.
In the docking analysis, the candidate pair received a Hex score of −656.83, compared with −515 for a TNFα–TNFR reference complex. These are computational docking scores, not measurements of signalling in cells. The authors state that experimental and clinical validation is needed before the findings can inform future interventions. The work is a bioRxiv preprint.